Literature DB >> 22169279

Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: review of international publications.

J Bruxelle1, S Pinchinat.   

Abstract

Herpes zoster is due to the reactivation of the virus causing varicella, called varicella-zoster virus. It affects peripheral nerves and causes painful skin and nerve lesions. This pain may last for months, or years after the initial lesions have resolved: post-herpetic neuralgia is the most frequent complication. Antiviral drugs, acting directly on the infectious agent are prescribed to reduce or block viral replication, relieve pain, and shorten symptom duration, especially for people of 50 years of age or more. However, there is currently no systematic collection of data concerning the effectiveness of antiviral drugs administered outside of clinical trials. This review evaluates the effectiveness of antiviral drugs on: (a) the intensity of pain and progression of the rash during the acute phase of herpes zoster, and (b) the frequency, intensity, and duration of post-herpetic neuralgia. During the acute phase, antiviral drugs (acyclovir, valacyclovir and famcyclovir) significantly reduce the intensity of acute pain, accelerate the healing of the vesicular rash, and reduce the duration of viral excretion. According to some authors, these drugs taken at an early stage of the disease would help to prevent the development of post herpetic neuralgia. But for others, there is no convincing evidence that antiviral drugs reduce the risk of painful complications.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169279     DOI: 10.1016/j.medmal.2011.11.001

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  5 in total

1.  ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?

Authors:  Martin Duracinsky; Marc Paccalin; Gaëtan Gavazzi; Sohéla El Kebir; Jacques Gaillat; Christophe Strady; Didier Bouhassira; Olivier Chassany
Journal:  BMC Infect Dis       Date:  2014-10-01       Impact factor: 3.090

Review 2.  Comparing Prodrugs with Acyclovir for Treating Postherpetic Neuralgia among Herpes Zoster Patients: A Systematic Review and Meta-Analysis.

Authors:  Chung-Hsin Yeh; Ko-Shih Chang; Sheng-Shiung Huang; Shiow-Luan Tsay; Jung-Mei Tsai; Ya-Jung Wang
Journal:  Healthcare (Basel)       Date:  2022-06-24

Review 3.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

Review 4.  Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider.

Authors:  Jamie S Massengill; John L Kittredge
Journal:  J Pain Res       Date:  2014-03-10       Impact factor: 3.133

Review 5.  Vaccination against herpes zoster in developed countries: state of the evidence.

Authors:  Mélanie Drolet; Michael N Oxman; Myron J Levin; Kenneth E Schmader; Robert W Johnson; David Patrick; James A Mansi; Marc Brisson
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.